Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box and leucine-rich repeat protein 15 (FBXL15) is a substrate recognition component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin-protein ligase complex, responsible for targeting specific proteins for ubiquitination and proteasomal degradation[1][2][9]. FBXL15 specifically mediates the ubiquitination and subsequent degradation of target proteins such as Smurf1, Smurf2, and WWP2, thus acting as a positive regulator of the bone morphogenetic protein (BMP) signaling pathway[1][2][4]. Through this regulation, FBXL15 plays a critical role in embryonic dorsal/ventral pattern formation, maintenance of bone mass, and transitions in the cell cycle[2][1]. Disease associations include bone density defects when FBXL15 is dysregulated, and possible connections to inherited diseases such as Bardet-Biedl syndrome 10 and neuronal ceroid lipofuscinosis[1][9]. As of now, there are no drugs, clinical biomarkers, or established safety concerns specifically associated with FBXL15[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box and leucine-rich repeat protein 15 (FBXL15).